Preparing for a novel era in CV prevention: where do PCSK9 inhibitors fit in lipid management?
Congress Presentation
About the speaker
Professor John Kastelein
4 more presentations in this session
Introduction - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.
Speaker: Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)
PCSK9, the short track road from discovery as drug target towards the clinic.
Speaker: Professor G. Lambert (SAINT DENIS, RE)
A clinical perspective on PCSK9 inhibition: what do we know and what can we expect?
Speaker: Doctor P. Ridker (Boston, US)
Discussion & summary - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.
Speaker: Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)
Access the full session
PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities
About the event
ESC 365 is supported by
